title: Fluticasone propionate: an effective alternative treatment for seasonal allergic rhinitis in adults and adolescents.
abstract: BACKGROUND
  Topical corticosteroids are widely regarded as the reference standard in allergic rhinitis therapy because they are well tolerated and effective against all rhinitis symptoms. We evaluated the efficacy, onset of action, and safety of two dosing regimens of the new corticosteroid fluticasone propionate compared with that of beclomethasone dipropionate in patients with moderate to severe seasonal allergic rhinitis.
  
  
  METHODS
  In this double-blind, randomized multicenter trial, 110 adolescents and 128 adults were treated for 4 weeks with one of the following regimens: fluticasone aqueous nasal spray 100 micrograms twice daily or 200 micrograms once daily, beclomethasone aqueous nasal spray 168 micrograms twice daily, or placebo.
  
  
  RESULTS
  Patient-rated scores for nasal obstruction, rhinorrhea, and combined nasal symptoms indicated that the two fluticasone regimens were equally effective and that both were superior to beclomethasone during most of the study (P < or = .05) and to placebo throughout the study (P < or = .01). Both fluticasone regimens also demonstrated significant clinical efficacy by 24 hours after the first dose. Clinician-rated mean total nasal symptoms scores for all three active treatments were superior to placebo at most time points but were not significantly different from each other. All treatments were well tolerated, with similar incidence and type of adverse events in all treatment groups and no apparent effects on hypothalamic-pituitary-adrenal (HPA) axis function.
  
  
  CONCLUSIONS
  Fluticasone aqueous nasal spray was effective in relieving nasal symptoms in adolescents and adults with seasonal allergic rhinitis. Fluticasone administered once or twice daily was superior to beclomethasone administered twice daily in relieving nasal obstruction and rhinorrhea and in reducing nasal symptoms more quickly.
authors.affiliation: Carolina Allergy & Asthma Consultants, PA, Raleigh, NC 27607.
authors.forename: C F
authors.initials: CF
authors.lastname: LaForce
authors.forename: R J
authors.initials: RJ
authors.lastname: Dockhorn
authors.forename: S R
authors.initials: SR
authors.lastname: Findlay
authors.forename: E O
authors.initials: EO
authors.lastname: Meltzer
authors.forename: R A
authors.initials: RA
authors.lastname: Nathan
authors.forename: W
authors.initials: W
authors.lastname: Stricker
authors.forename: S
authors.initials: S
authors.lastname: Weakley
authors.forename: E A
authors.initials: EA
authors.lastname: Field
authors.forename: P R
authors.initials: PR
authors.lastname: Rogenes
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000730:Androstadienes / Q000008:administration & dosage / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001507:Beclomethasone / Q000008:administration & dosage / Q000627:therapeutic use; D002648:Child; D004311:Double-Blind Method; D005260:Female; D000068298:Fluticasone; D005938:Glucocorticoids; D006801:Humans; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D000730:Androstadienes; D000893:Anti-Inflammatory Agents; D005938:Glucocorticoids; D000068298:Fluticasone; D001507:Beclomethasone